Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.

Similar presentations


Presentation on theme: "Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L."— Presentation transcript:

1 Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L. Rascati, PhD, Eui-Kyung Lee, PhD  Value in Health Regional Issues  Volume 12, Pages 7-19 (May 2017) DOI: /j.vhri Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2 Fig. 1 The diagram of Korea National Health Insurance before and after the reference pricing system. Value in Health Regional Issues  , 7-19DOI: ( /j.vhri ) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3 Fig. 2 Savings rate on prescription ingredient costs for chemical-level model, therapeutic- level model, and hybrid grouping model under scenarios. Note. Savingsrate(%)=Originalprescriptioningredientcosts($)−Prescriptioningredientcostsunderexpectedscenarios($)Originalprescriptioningredientcosts($) Value in Health Regional Issues  , 7-19DOI: ( /j.vhri ) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4 Fig. 3 Patient co-payments for chemical-level, therapeutic-level, and hybrid grouping models under scenarios. Note. Baseline represents original co-payments for patients before the reference pricing system. Baseline co-pay rate: chemical level, 20.4%; therapeutic level, 20.4%; hybrid grouping model, 22.9%. Value in Health Regional Issues  , 7-19DOI: ( /j.vhri ) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5 Fig. 3 Patient co-payments for chemical-level, therapeutic-level, and hybrid grouping models under scenarios. Note. Baseline represents original co-payments for patients before the reference pricing system. Baseline co-pay rate: chemical level, 20.4%; therapeutic level, 20.4%; hybrid grouping model, 22.9%. Value in Health Regional Issues  , 7-19DOI: ( /j.vhri ) Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions


Download ppt "Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L."

Similar presentations


Ads by Google